All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treating classical Hodgkin lymphoma: Spotlight on targeted therapies

with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce

Saturday, November 2, 2024
8:50-9:50 CET

Register now

This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2019-06-18T10:00:46.000Z

EHA 2019 | Updated analysis from the HORIZON study of melflufen in RRMM

By Emily Smith, Paul Richardson
Jun 18, 2019
Share:

At the 24th Congress of the European Hematology Association (EHA), Paul G. Richardson from the Dana-Farber Cancer Institute, Boston, US, speaks to the Multiple Myeloma Hub about the updated analysis from the HORIZON study of melflufen in relapsed/refractory multiple myeloma (RRMM).

 
The HORIZON study is a phase II trial of melflufen + dexamethasone for patients with RRMM resistant to pomalidomide or daratumumab, or both. The majority of enrolled patients were triple class refractory, representing a very vulnerable population with few other treatment options. This study was in conducted in over 120 patients, with triple refractory disease, of whom nearly 60% had high-risk disease, and some had extra-medullary disease.
 
Melflufen delivers chemotherapy directly, minimizing the toxicity in normal tissue and maximizing it with the cancer cells.
 
The study found around a third of patients responded to treatment, with a median progression-free survival (PFS) of 4 months and a median overall survival approaching 10 months. Prof. Richardson highlighted though that this is an ongoing study.
 
The side effect profile was manageable, with no high rates of serious infection which Prof. Richardson highlighted was important in this vulnerable group.
 
Other studies, such as the ANCHOR study, are ongoing. In the ANCHOR study, melflufen is combined with bortezomib in one arm, reporting response rates of 100%, and daratumumab in another arm, with response rates of over 80%.

Updated analysis from the HORIZON study of melflufen in RRMM

More about...
BortezomibDaratumumabDexamethasoneEHAEHA 2019HORIZONMelflufenPomalidomideRelapsed/refractory multiple myeloma

Your opinion matters

HCPs, what is your preferred format for educational content on the Multiple Myeloma Hub?
48 votes - 9 days left ...

Related articles

Add bookmark

ASCO 2019 | Phase I study of iberdomide (IBER) in relapsed/refractory multiple myeloma 

The phase Ib/IIa results (NCT02773030) of iberdomide (IBER, CC 220) for the treatment of relapsed/refractory multiple myeloma (RRMM) presented at ASCO 2019.

Jun 17, 2019
Add bookmark

ASCO 2019 | Phase I study of iberdomide (IBER) in relapsed/refractory multiple myeloma 

The phase Ib/IIa results (NCT02773030) of iberdomide (IBER, CC 220) for the treatment of relapsed/refractory...

Jun 17, 2019
Add bookmark

EHA 2018 | The phase III OPTIMISMM study of pomalidomide, bortezomib and dexamethasone

Pomalidomide, bortezomib, and dexamethasone reduced the risk of progression or death by 39%, compared to treatment with bortezomib, and dexamethasone alone in...

Jun 28, 2018
Add bookmark

EHA 2018 | The phase III OPTIMISMM study of pomalidomide, bortezomib and dexamethasone

Pomalidomide, bortezomib, and dexamethasone reduced the risk of progression or death by 39%, compared to...

Jun 28, 2018

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox